131830-52-9

Upstream product

• 2930-05-4 Benzyloxymethyl-oxiran 
• 1730-25-2 allylmagnesium bromide 
• 60656-87-3 benzyloxyacetoaldehyde 
• 7103-09-5 4-but-1-enylmagnesium bromide 
• 18001-18-8 allyldimethylphenylsilane 
• 17922-43-9 allyldiphenyl(methyl)silane 
• 24400-84-8 allyl triisopropylsilane 
• 762-72-1 allyl-trimethyl-silane 
• 5162-44-7 1-bromo-4-butene 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 79494-91-0 5-<(benzyloxy)methyl>tetrahydrofuran-2-methanol 
• 151238-11-8 6-(Benzyloxy)-5-bromo-1-hexene 
• 151238-12-9 6-(Benzyloxy)-5-(p-toluenesulfonyloxy)-1-hexene 
• 1185060-05-2 (+/-)-1-(benzyloxy)hex-5-en-2-yl 4-nitrophenylsulfonylcarbamate 
• 226253-68-5 5-(benzyloxy)-4-oxopentanal 
• 1422278-63-4 (1S,2S,3S,4R)-1-((benzyloxy)methyl)-3-methyl-3-(4-methylpent-3-en-1-yl)-2-vinylcyclohexane-1,4-diol 
• 1422278-64-5 (1R,2R,3R,4S)-1-((benzyloxy)methyl)-3-methyl-3-(4-methylpent-3-en-1-yl)-2-vinylcyclohexane-1,4-diol 
• 851786-79-3 (1-benzyloxymethyl-pent-4-enyloxy)-tert-butyl-dimethyl-silane 
• 1257867-27-8 6-(benzyloxymethyl)-N-tosylpiperidin-2-one 
• 1257867-40-5 N-benzyl-1-(benzyloxy)hex-5-en-2-amine 
• 1257867-39-2 1-(benzyloxy)hex-5-en-2-one 
• 1257867-24-5 5-(benzyloxymethyl)-N-tosylpyrrolidine-2-carbaldehyde 
• 1257867-38-1 (5-(benzyloxymethyl)-N-tosylpyrrolidin-2-yl)methanol 
• 1257867-37-0 N-(1-(benzyloxy)hex-5-en-2-yl)-4-methylbenzenesulfonamide 

Relevant academic research and scientific papers

Gram-Scale Synthesis of the Co(nmp) 2 Catalyst to Prepare trans -2,5-Disubstituted Tetrahydrofurans by the Aerobic Oxidative Cyclization of Pent-4-en-1-ols

Co(nmp) 2 is an efficient catalyst for the aerobic oxidative cyclization of pent-4-en-1-ols to give 5-hydroxymethyl trans -tetrahydrofurans (THFs) as single diastereomers in high yield. The trans -THF pharmacophore is of interest because it is

Skipped Fluorination Motifs: Synthesis of Building Blocks and Comparison of Lipophilicity Trends with Vicinal and Isolated Fluorination Motifs

Given there is an optimal lipophilicity range for orally bioavailable drugs, structural modifications applied in the drug development process are not only focused on optimizing bioactivity but also on fine-tuning lipophilicity. Fluorine introduction can b

PYRIDAZINONES AS PARP7 INHIBITORS

The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

Cobalt-Catalyzed Stereoselective Synthesis of 2,5- trans-THF Nitrile Derivatives as a Platform for Diversification: Development and Mechanistic Studies

A straightforward protocol integrating a sustainable approach for the synthesis of new 2,5-trans-THF nitrile derivatives enabling an easy diversification of its side chain scaffolds is described. The reaction tolerated different aromatic and alkyl substit

A catalytic enantioselective tandem allylation strategy for rapid terpene construction: Application to the synthesis of pumilaside aglycon

Catalytic enantioselective 1,2-diboration of 1,3-dienes followed by cascade allylborations with dicarbonyls provides rapid entry into carbocyclic reaction products. The stereochemical course of this reaction was studied along with its application in the synthesis of pumilaside aglycon.

Synthesis of tetrahydrofurans by the reaction of α,β-epoxy alcohol derivatives with allylsilanes

In the presence of SnCl4, α,β-epoxy alcohol derivatives easily reacted with allylsilanes to give the corresponding tetrahydrofurans in moderate yields.

A General and Facile Synthesis of β- and γ-Hydroxy Phosphonates from Epoxides

A practical and facile method for the preparation of hydroxy phosphonate esters is described.Regiospecific ring opening of monosubstituted epoxides by phosphorus and carbon nucleophiles, derived from diethyl phosphite and methanephosphonates, in the prese

Disubstituted tetrahydrofurans and dioxolanes as PAF antagonists

A new series of disubstituted tetrahydrofuran and dioxolane derivatives were prepared and evaluated for their PAF antagonist activity in the PAF-induced in vitro platelet-aggregation and in vivo hypotension tests. Several of these compounds exhibited more potent activity than the structurally related 2-[N-acetyl-N-[[[[2-methoxy-3-[(octadecylcarbamoyl)oxy]propoxy] carbonyl]amino]methyl]-1-ethylpyridinium chloride (CV-6209, 3) in the in vitro assay, whereas all showed less potency in the in vivo test. The role of both the substituent nature and the placement and number of oxygen atoms in the ring are discussed. A qualitative SAR study was carried out on these nuclei.

New 2,5-disubstituted tetrahydrofuran derivatives

The present invention relates to new derivatives of 2,5--disubstituted tetrahydrofurans with a potent antagonist activity of the platelet activating factor (PAF), together with a process for their preparation. The invention also relates to the pharmaceutical preparations which contain these compounds an their use in the treatment of diseases in which PAF is involved, such as allergic and bronchial asthma, platelet aggregation disorders, septic shock, hypertension, etc.